Koers DiaMedica Inc. Toronto S.E.
Aandelen
DMA
CA25253T1075
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- CAD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 156 mln. 114 mln. 106 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -37 mln. -27,02 mln. -25,13 mln. | Nettowinst (verlies) 2025 * | -47 mln. -34,32 mln. -31,92 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-4,23
x | K/w-verhouding 2025 * |
-3,61
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 61,96% |
Recentste transcriptie over DiaMedica Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 01-04-05 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 01-04-18 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 30-05-23 |
Tanya Lewis
BRD | Director/Board Member | 53 | 01-03-23 |
James Parsons
BRD | Director/Board Member | 58 | 20-10-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |
- Beurs
- Aandelen
- Koers DMAC
- Koers DMA